SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $494,653 | -96.1% | 34,067 | -94.4% | 0.01% | -96.1% |
| Q2 2023 | $12,815,774 | -32.4% | 612,316 | -22.4% | 0.15% | -42.6% |
| Q3 2022 | $18,966,000 | +179.2% | 789,273 | +154.3% | 0.26% | +173.2% |
| Q4 2021 | $6,794,000 | -38.8% | 310,377 | -46.6% | 0.10% | -46.4% |
| Q3 2021 | $11,109,000 | +211.4% | 581,308 | +179.7% | 0.18% | +170.1% |
| Q2 2021 | $3,568,000 | +106.5% | 207,812 | +167.5% | 0.07% | +45.7% |
| Q4 2020 | $1,728,000 | – | 77,699 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |